157 related articles for article (PubMed ID: 33947152)
1. Pharmacological Inhibition of miR-130 Family Suppresses Bladder Tumor Growth by Targeting Various Oncogenic Pathways via PTPN1.
Monoe Y; Jingushi K; Kawase A; Hirono T; Hirose R; Nakatsuji Y; Kitae K; Ueda Y; Hase H; Abe Y; Adachi J; Tomonaga T; Tsujikawa K
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33947152
[TBL] [Abstract][Full Text] [Related]
2. MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer.
Koutsioumpa M; Chen HW; O'Brien N; Koinis F; Mahurkar-Joshi S; Vorvis C; Soroosh A; Luo T; Issakhanian S; Pantuck AJ; Georgoulias V; Iliopoulos D; Slamon DJ; Drakaki A
Mol Cancer Ther; 2018 Jul; 17(7):1430-1440. PubMed ID: 29703843
[TBL] [Abstract][Full Text] [Related]
3. Invasion-related circular RNA circFNDC3B inhibits bladder cancer progression through the miR-1178-3p/G3BP2/SRC/FAK axis.
Liu H; Bi J; Dong W; Yang M; Shi J; Jiang N; Lin T; Huang J
Mol Cancer; 2018 Nov; 17(1):161. PubMed ID: 30458784
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-361-3p is a potent therapeutic target for oral squamous cell carcinoma.
Ogawa H; Nakashiro KI; Tokuzen N; Kuribayashi N; Goda H; Uchida D
Cancer Sci; 2020 May; 111(5):1645-1651. PubMed ID: 32086979
[TBL] [Abstract][Full Text] [Related]
5. Methyl jasmonate sensitizes human bladder cancer cells to gambogic acid-induced apoptosis through down-regulation of EZH2 expression by miR-101.
Wang Y; Xiang W; Wang M; Huang T; Xiao X; Wang L; Tao D; Dong L; Zeng F; Jiang G
Br J Pharmacol; 2014 Feb; 171(3):618-35. PubMed ID: 24490857
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.
Di Martino MT; Gullà A; Gallo Cantafio ME; Altomare E; Amodio N; Leone E; Morelli E; Lio SG; Caracciolo D; Rossi M; Frandsen NM; Tagliaferri P; Tassone P
PLoS One; 2014; 9(2):e89659. PubMed ID: 24586944
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-124-3p suppresses cell migration and invasion by targeting ITGA3 signaling in bladder cancer.
Wang JR; Liu B; Zhou L; Huang YX
Cancer Biomark; 2019; 24(2):159-172. PubMed ID: 30614803
[TBL] [Abstract][Full Text] [Related]
8. miR-202 Inhibits Cell Proliferation, Migration, and Invasion by Targeting Epidermal Growth Factor Receptor in Human Bladder Cancer.
Zhang L; Xu J; Yang G; Li H; Guo X
Oncol Res; 2018 Jul; 26(6):949-957. PubMed ID: 29298735
[TBL] [Abstract][Full Text] [Related]
9. miR-451 suppresses bladder cancer cell migration and invasion via directly targeting c-Myc.
Wang J; Zhao X; Shi J; Pan Y; Chen Q; Leng P; Wang Y
Oncol Rep; 2016 Oct; 36(4):2049-58. PubMed ID: 27571748
[TBL] [Abstract][Full Text] [Related]
10. Platycodin D (PD) regulates LncRNA-XIST/miR-335 axis to slow down bladder cancer progression in vitro and in vivo.
Chen D; Chen T; Guo Y; Wang C; Dong L; Lu C
Exp Cell Res; 2020 Nov; 396(1):112281. PubMed ID: 32919956
[TBL] [Abstract][Full Text] [Related]
11. Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression.
Murphy BL; Obad S; Bihannic L; Ayrault O; Zindy F; Kauppinen S; Roussel MF
Cancer Res; 2013 Dec; 73(23):7068-78. PubMed ID: 24145352
[TBL] [Abstract][Full Text] [Related]
12. HIF-1α-dependent miR-424 induction confers cisplatin resistance on bladder cancer cells through down-regulation of pro-apoptotic UNC5B and SIRT4.
Yu M; Ozaki T; Sun D; Xing H; Wei B; An J; Yang J; Gao Y; Liu S; Kong C; Zhu Y
J Exp Clin Cancer Res; 2020 Jun; 39(1):108. PubMed ID: 32522234
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy.
Li H; Yu G; Shi R; Lang B; Chen X; Xia D; Xiao H; Guo X; Guan W; Ye Z; Xiao W; Xu H
Mol Cancer; 2014 Jan; 13():8. PubMed ID: 24423412
[TBL] [Abstract][Full Text] [Related]
14. Pristimerin inhibits glioma progression by targeting AGO2 and PTPN1 expression via miR-542-5p.
Li Z; Hu C; Zhen Y; Pang B; Yi H; Chen X
Biosci Rep; 2019 May; 39(5):. PubMed ID: 31015365
[TBL] [Abstract][Full Text] [Related]
15. miR-130b, an onco-miRNA in bladder cancer, is directly regulated by NF-κB and sustains NF-κB activation by decreasing Cylindromatosis expression.
Cui X; Kong C; Zhu Y; Zeng Y; Zhang Z; Liu X; Zhan B; Piao C; Jiang Z
Oncotarget; 2016 Jul; 7(30):48547-48561. PubMed ID: 27391066
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function.
Bernardo BC; Gao XM; Winbanks CE; Boey EJ; Tham YK; Kiriazis H; Gregorevic P; Obad S; Kauppinen S; Du XJ; Lin RC; McMullen JR
Proc Natl Acad Sci U S A; 2012 Oct; 109(43):17615-20. PubMed ID: 23047694
[TBL] [Abstract][Full Text] [Related]
17. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
Matalkah F; Martin E; Zhao H; Agazie YM
Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
[TBL] [Abstract][Full Text] [Related]
18. MiR-15 suppressed the progression of bladder cancer by targeting BMI1 oncogene via PI3K/AKT signaling pathway.
Zhang L; Wang CZ; Ma M; Shao GF
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8813-8822. PubMed ID: 31696468
[TBL] [Abstract][Full Text] [Related]
19. miR-130b promotes bladder cancer cell proliferation, migration and invasion by targeting VGLL4.
Liu X; Kong C; Zhang Z
Oncol Rep; 2018 May; 39(5):2324-2332. PubMed ID: 29512748
[TBL] [Abstract][Full Text] [Related]
20. miR-186 downregulates protein phosphatase PPM1B in bladder cancer and mediates G1-S phase transition.
Yang J; Yuan D; Li J; Zheng S; Wang B
Tumour Biol; 2016 Apr; 37(4):4331-41. PubMed ID: 26494000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
